The relationship between acute lymphoblastic leukemia (ALL-L3) and stage IV small noncleaved cell lymphoma with bone marrow involvement (SNCL) was analyzed by retrospective study of 45 patients. Twelve patients with ALL-L3 had tumor restricted to the marrow and blood with no evidence of an extramedullar) tumor at their initial presentation. Nineteen patients with stage IV SNCL had evidence of extramedullary disease in addition to marrow and blood involvement. Fourteen patients with marrow and blood involvement by SNCL at the time of a first or second relapse were also studied. The median age of the ALL-L3 patients was 33.5 years, compared with 13 years for the patients with stage IV SNCL and 10.5 years for the marrow relapse patients. All of the ALL-L3 patients were male; the male:female ratio for the SNCL patients was 17:2; for the relapse group, 9:5. The majority of the ALL-L3 patients had symptoms related to bone marrow failure; the majority of the SNCL patients had symptoms related to a tumor mass.
Laboratory values at the time of initial diagnosis were similar for the ALL-L3 and SNCL patients, except that the median platelet count was lower in the ALL-L3 group. Despite extensive marrow involvement by tumor in most patients, frankly leukemic blood pictures were uncommon. Light-chain-restricted surface immunoglobulin on tumor cells was a consistent finding in all cases tested; the findings were similar in the three groups. Cytogenetic data, available for 19 cases, showed no difference between cases with and without extramedullary disease. The median survival was 5.1 months for ALL-L3 patients and 3.2 months for SNCL patients. The median survival from the time of bone marrow relapse was 2.3 months. These observations suggest that ALL-L3 and SNCL represent different manifestations of the same disease process. (Key words: Bone marrow; Burkitt's lymphoma; Cytogenetics; L3 acute lymphoblastic leukemia; morphology; Small noncleaved cell lymphoma) Am J Clin Pathol 1994;101:130-139.
MATERIALS AND METHODS

Case Selection
The patient population consisted of 45 cases satisfying the morphologic criteria of ALL-L3 or marrow involvement by SNCL, diagnosed in the Hematopathology Section of the University of Minnesota Hospitals (UMHC) from January 1970 to December 1990. In 31 of the cases, marrow involvement was present at initial diagnosis. These 31 cases were separated into ALL-L3 (group 1, 12 patients) and SNCL (group 2, 19 patients), based on the presence or absence of an extramedullary mass. L3 acute lymphoblastic leukemia was defined as tumor in the marrow and blood with no evidence of a tissue mass or localized lymphadenopathy on physical or radiographic examination. In 14 cases of SNCL (group 3), the initial marrow involvement occurred at the time of a first or second relapse. All patients were managed at some time during the course of their disease on the medical or pediatric services at UMHC; all clinical records were available for review.
Morphology
Bone marrow trephine biopsies and aspirates were performed and processed in a manner previously reported. 1 Blood and bone marrow smears and trephine imprints were stained L3 Acute Lymphoblastic Leukemia with a Wright's-Giemsa technique. The bone marrow trephine biopsy sections were stained with hematoxylin and eosin. Criteria for Burkitt's morphology were those published by the World Health Organization. 2 The distinction between Burkitt's and non-Burkitt's morphology was determined from bone marrow trephine biopsy section histology and bone marrow aspirate smears. Criteria for non-Burkitt's morphology were based on published studies making this distinction. 
Hematology
Pretreatment hematology values were obtained from patient records for patients in groups 1 and 2.
Immunologic Markers
Immunophenotyping was performed on specimens from 19 of 31 patients in groups 1 and 2; bone marrow aspirates were performed on 11 patients, and extramedullary lesions on 8. Immunophenotyping was performed on specimens from 9 of the 14 patients in group 3; 4 on extramedullary lesions at initial diagnosis, 1 on an extramedullary tumor at relapse, 3 on bone marrow aspirates at relapse, and 1 on peripheral blood at relapse. Immunophenotyping was performed as previously reported. 7, 8 Light-chain determination was only performed on the cells from patient 29. Heavy-chain determination was only performed on the cells from patient 34.
Cytogenetics
Banded chromosome analysis was successfully performed on 19 patients, including 2 patients in group 1,9 in group 2, and 8 in group 3. Bone marrow (n = 7) or blood (n = 2) from nine patients in groups 1 and 2 was analyzed at diagnosis; marrow obtained from the remaining two patients was analyzed after one dose of chemotherapy or at relapse. Among the group 3 patients, tumor tissue obtained at diagnosis was analyzed in one case; marrow (n = 5), blood (n = 1), or tumor mass (n = 1) obtained at relapse were analyzed in the remaining seven cases.
Chromosome analysis was done at UMHC in 15 of the 19 cases. The remaining four cases (patients 14, 29, 38, and 44) were analyzed at other institutions, and results were obtained from patient records. The UMHC analyses were done using standard methods. Metaphase cells were harvested from direct preparations and short-term (24-48 hours), unstimulated cultures of fresh, heparinized blood or bone marrow aspirates, or from single-cell suspensions of fresh tumor mass. Chromosomes were G-banded using Wright's stain. 9 Karyotypes were designated according to the International System for Human Cytogenetic Nomenclature (1985) . 
Additional Laboratory Studies
Serum lactate dehydrogenase and serum uric acid determinations were performed on pretherapy specimens.
Statistical Analysis
The significance of differences between groups 1 and 2 was tested using a 2-tail Fisher's exact test and a 2-tail Mann-Whitney rank sum test."
Survival Data
Complete remission was defined as the absence of clinical and laboratory evidence of disease. Partial response was defined as a reduction of at least 50% in tumor mass, with residual disease remaining at completion of therapy. No response was defined as less than 50% reduction in tumor mass or an increase in tumor mass at the conclusion of therapy. Follow-up data were available for all patients in the study. Survival was computed from date of initial diagnosis to date of death.
RESULTS
Clinical Features
Groups 1 and 2. The age range for the 12 patients in group 1 was 6 to 63 years, with a median of 33.5. The age range for the 19 patients in group 2 was 3 to 76 years, with a median of 12.5. All patients in group 1 were male; group 2 consisted of 17 males and two females. The difference between the sex ratios for the two groups was not statistically significant (P = .5097).
The clinical findings for groups 1 and 2 are shown in Tables 1  and 3 . Eight of the 12 group 1 patients had been admitted with bleeding or bruising, three with bone pain, and one with infection. Eleven of the 19 group 2 patients had pain or paresthesias related to a tumor mass; three of the other eight patients had an oropharyngeal mass, one had symptoms of bowel obstruction, one had infection, and one had abnormal bruising. None of the group I patients had tumor cells in the cerebrospinal fluid (CSF) at the time of initial diagnosis; four of the 12 had CSF relapses. Four of the 19 group 2 patients had tumor cells in the CSF at initial diagnosis, and seven had CSF tumor cells at relapse. 
L3 Acute Lymphoblastic Leukemia
Hematology
Laboratory findings for groups 1 and 2 are listed in Tables 2  and 3 . There was no significant difference in hemoglobin or total leukocyte counts between the two groups. The hemoglobin was less than 12 gm/dL in 15 of the 31 patients. The leukocyte counts ranged from 1.5 X 109/L to 89.2 X 109/L, with a median of 10.0. Although patients in both groups typically had thrombocytopenia, the median platelet count was significantly lower in patients in group 1 (P = .009). The percentage of blasts in the marrow and blood was similar in the two groups. In contrast to the high median blast percentages in the marrow, the percentage of blasts in the blood was usually low.
Cytomorphology
The basic cytologic characteristics of the neoplastic cells in the blood and marrow smears and trephine imprints were similar in all cases (Figs. 1-4 ). There were no differences between the cases classified as ALL-L3 or marrow involvement by SNCL. The major cell type was medium-sized, 16 The cases classified as Burkitt's-type ( Figs. 1 and 2 ) showed some variation in nuclear size, from 7 to 14 ^m; the variation was seen in less than 25% of the cells within a case. The nuclear outlines were regular, and the amount of cytoplasm was generally uniform. The nuclei contained two to four distinct, but not unusually prominent, nucleoli.
More variation in nuclear size was seen in the non-Burkitt's cases (Figs. 3 and 4) . Irregular nuclear contours were present in more than 25% of the cells. Nucleoli were more prominent than in the cases classified as Burkitt's type. The amount of cytoplasm was more variable, ranging from scant to moderate.
Histopathology
The trephine biopsy specimens generally showed extensive marrow replacement by the malignant process (Figs. 5-8 ). The cases classified as ALL-L3 were uniform in showing complete replacement of the marrow; two cases showed some sparing of megakaryocytes (patients 6 and 10). Two of SNCL cases showed partial replacement of the marrow; two had substantial sparing of normal marrow cells (Fig. 9) . One of the SNCL cases, which had extensive marrow replacement, showed sparing of megakaryocytes (patient 21).
Of the 31 patients with marrow involvement by tumor at diagnosis (groups 1 and 2), 24 had Burkitt's and seven had non-Burkitt's morphology (Table 3 ). The proportion of group 1 patients with non-Burkitt's morphology was not significantly different from that of group 2 (P = .676). Four of the 14 patients in the marrow relapse group (group 3) had non-Burkitt's morphology, which is similar to the proportion of patients who had non-Burkitt's morphology at initial diagnosis.
There was relative uniformity of cell size and nuclear shape in the Burkitt's-type cases. A distinct cytoplasmic rim was present; vacuoles were not as readily appreciated as in smears and imprints. The nuclear outline was round to ovoid; nucleoli were distinct but not unusually prominent. In the non-Burkitt's cases, there was substantial variation in cell size and nuclear shape (Figs. 7 and 8 ). Cytoplasmic borders were distinct, but the amount of cytoplasm was more variable than in the Burkitt's type. Irregular and cleaved nuclei were present in some cases. Nucleoli were more prominent than in the Burkitt's type and more typically centrally located. Mitotic activity was prominent in both Burkitt's and non-Burkitt's types. Sin- gle-cell necrosis was present in several cases; in two cases, diffuse necrosis was present. Starry sky macrophages were found in six cases.
Cell Surface Immunoglobulin
The cell surface immunoglobulins (SIg) in groups 1 and 2 are presented in Table 2 ; those in group 3 are presented in Table 4 . Monoclonal SIg was present in all cases tested. The majority of cases of both Burkitt's and non-Burkitt's subtypes were IgM*.
Cytogenetic Results
The results of the cytogenetic analyses are summarized in Table 5 . Specimens for 17 of the 19 patients had translocations typically associated with Burkitt's lymphoma or leukemia; 16 had a t(8;14)(q24;q32) and one had a t(2;8)(pl l;q24). Additional abnormalities were found in 14 of the 17 cases. The most common secondary abnormality was duplication or an extra copy of part of the long arm of chromosome 1. 
Serum Chemistries
Serum lactate dehydrogenase and uric acid values at diagnosis for patients in groups I and II are summarized and contrasted in Table 3 . The values are not significantly different for the two groups (P = .835). All patients with marrow involvement by tumor had elevated levels of serum lactate dehydrogenase. Although some patients had values within the normal range, uric acid levels were typically elevated.
Therapy, Response, and Survival
Groups 1 and 2. The survival data for patients in groups 1 and 2 are shown in Table 2 and summarized in Table 3 . All patients in these groups received multiagent chemotherapy. Six of the 12 group 1 patients achieved complete remission, three had a partial response, and three no response to initial therapy. Eleven of the 19 group 2 patients achieved complete remission, five had a partial response, and three had no response. The median survival was comparable for the two groups. There were two long-term survivors (disease-free survival & 18 months) in each group. None of the long-term survivors had renal failure caused by tumor lysis or CSF involvement at any time during the disease course. All long-term survivors from both groups had Burkitt's morphology. The median survival was 9 months for Burkitt's morphology patients, as compared with 3.3 months for patients with non-Burkitt's morphology.
Group 3. The survival data for patients in group 3 are listed in Table 4 . All patients received multiagent chemotherapy; all had a complete or partial response to induction therapy. None of the group 3 patients had renal failure requiring hemodialysis during initial therapy. The median time to marrow relapse for this group was 8.3 months. The median survival from the time of diagnosis was 10.3 months; the median survival from the time of marrow relapse was 2.3 months. The single long-term survivor in group 3 had Burkitt's morphology. All 13 group 3 patients who did not survive had evidence of tumor at the time of death. The median survival of the 13 patients from groups 1-3 who received bone marrow transplants was 10.2 months. L3 Acute Lymphoblastic Leukemia   FIG. 9 . Bone marrow trephine biopsy section from patient 24, demonstrating significant marrow sparing by lymphoma. Hematoxylin and eosin, X 160.
DISCUSSION
In 1976 the French-American-British cooperative group proposed a classification system for acute leukemias that included a category of acute lymphoblastic leukemia referred to as L3. 12 Acute lymphoblastic leukemia-L3 was described as having a monomorphic cell population with the cytologic characteristics of Burkitt's lymphoma. 2 The relationship of ALL-L3 to Burkitt's lymphoma or the small noncleaved cell lymphoma, Burkitt's and non-Burkitt's types, of the Working Formulation has been problematic. Because of the marked cytologic and histologic similarities of these two lesions, ALL-L3 is viewed by some observers as the blood and marrow manifestation of a small noncleaved cell lymphoma. In some reports, SNCL with marrow involvement at diagnosis is referred to as ALL-L3. 13 Thirty-one of the 45 patients presented here were studied at initial diagnosis; ALL-L3 was diagnosed in 12 of the 31 (group 1), and marrow involvement by small noncleaved cell lymphoma was diagnosed in 19 (group 2). The designation of ALL- (9)t(?6;9)(?p2l;q22) Clone 2:47,XY,+Y,-9,-13,t(8; 14)(q24;q32),+der(9)t(?6;9)(?p21 ;q22), +der(13)t(l;13)(q21;q32) 46.XY,-11,-13,dir dup( 1 )(q21 -»q25),del(2)(p21 p25),del(2)(q3?3q37), del(9)(ql3q32)t(8;14)(q24;q32),+der(l l)t(I l;?)(q2?5;?), +der(13)t(13;?)(q32;?)
L3 was used for those cases in which the tumor process was restricted to the marrow and blood with no physical or radiographic evidence of extramedullary involvement. The 19 patients with SNCL with marrow involvement had extramedullary evidence of tumor. Fourteen patients with SNCL without marrow involvement at initial diagnosis were studied at the time of a bone marrow relapse (group 3). There were no statistically significant differences in either age at presentation or sex ratio for the ALL-L3 or SNCL with marrow involvement groups. Both showed a marked male predominance, which had been previously reported for ALL-L3. 14 
"
16 Hematologic values at the time of disease presentation were not significantly different for the two groups, except that the platelet count tended to be lower for patients with ALL-L3.
As expected, the marrow cytomorphology and histology were identical for both the ALL-L3 and marrow involvement by SNCL cases. Although ALL-L3 is defined as having homogeneous blast morphology, the lymphoblasts in two of the 12 cases classified as ALL-L3 had cytologic characteristics similar to the non-Burkitt's type of SNCL. This was not significantly different from the proportion of cases of SNCL exhibiting nonBurkitt morphology (P = .676).
The presence of light-chain-restricted surface immunoglobulin on the tumor cells was a consistent finding in all of the groups. There was a predominance of K light chain in both ALL-L3 and SNCL cases. This contrasts with the X light chain predominance previously reported in cases of small noncleaved cell lymphoma. 5 The cytogenetic findings in these cases are similar to those reported previously. 17 " 20 Seventeen of the 19 patients had either a t(8;14)(q24;q32) or a t(2;8)(pl l;q24); both of these translocations have been found to be associated with ALL-L3 and SNCL. 171820 Fourteen of these 17 patients also had additional karyotypic abnormalities, the most common being duplication or trisomy of part of the long arm of chromosome 1. Duplication of part of 1 q was also the most common additional change found in patients with translocations involving 8q24, studied at the Fifth International Workshop on Chromosomes in Leukemia-Lymphoma. 19 In our study, ALL-L3 and SNCL were cytogenetically indistinguishable .
Because the patients in this study were accumulated over an extended period, treatment regimens varied. However, the treatment regimen for both ALL-L3 and SNCL with marrow involvement was similar, and the median survival was similar for patients in both groups: 5.1 months for ALL-L3 and 3.2 months for SNCL with marrow involvement. This is shorter than the median survival of 7-10 months for stage IV SNCL, reported in other studies, which included primarily stage IV L3 Acute Lymphoblastic Leukemia tumors with visceral but no marrow involvement. 3A21 Although previous studies have shown that prognosis in Burkitt's lymphoma is directly related to total tumor burden, the median survival in the present series is similar for patients with ALL-L3 and SNCL with bulky disease and marrow involvement. 22 Two group 1 patients and two group 2 patients survived free of disease for more than 18 months; all four patients had Burkitt-type histology. This finding is similar to other studies, in which disease free survival in SNCL was associated with Burkitt-type morphology. 4, 5 It has been suggested that this finding may be an artifact of failure to control for age and that long-term survival may be a feature of younger patients. 23 The four long-term survivors in this study were less than 35 years of age. There was no age predilection for CSF involvement or renal failure due to tumor lysis syndrome associated with initial therapy in this group of patients. None of the patients with renal failure or CSF involvement were among the long-term survivors.
Acute lymphoblastic leukemia L3 and small noncleaved cell lymphoma are morphologically indistinguishable in blood and marrow specimens. The major difference between these two processes is clinical presentation. Patients with ALL-L3 characteristically have symptoms related to bone marrow failure and no evidence of extramedullary tumor; there is a marked male predominance. Patients with stage IV SNCL usually have symptoms referable to a tumor mass; these patients may have marrow involvement and some evidence of marrow failure. The number of lymphoblasts in the blood and marrow is similar in the two groups. There are no distinguishing cytogenetic or immunologic findings, and response to therapy and survival are similar. These observations suggest that ALL-L3 and SNCL represent different manifestations of the same disease process. Previous observations have supported the follicular center as the site of origin of the SNCL. In view of this observation, the origin of ALL-L3 in most cases would be in an extramedullary site.
